Leading pharmaceutical corporation AstraZeneca said that its recent antibody cocktail showed more positive results in latest study, Reuters reported on Friday.
The study showed that a cocktail of two types of antobodies managed to reduce the risks of COVID-19 symptoms with 77%, in addition to reducing COVID-19 linked deaths.
The latest results renewed the hope of the giant drug-maker company as this cocktail didn't express the expected results in a previous trial. Therefore, AstraZeneca aims to present a new alternative for vaccines for people who are in direct contact with infections.
It is worthy to mention that AstraZeneca was one of the earliest firms that manufactured COVID-19 vaccine, in addition, it is one of the few approved vaccines world.
In July, a study showed that two shots of Pfizer or AstraZeneca vaccine are highly effective against the latest Delta COVID-19 variant.
Although various experts announced previously that all approved vaccines are effective against the highly transmissible strain, scientists showed that one shot of the vaccine is not enough for securing from the variant. The two shots are required.
Published in the New England Journal of Medicines, it asserted that the high efficiency of both two-shot vaccines against the Delta strain, and it is based on “real-world data,” according to Reuters.
The two-dose-Pfizer was effective by 88% against Delta strain, compared to 93.7% against the earliest variants of COVID-19, Alpha strain.
On the other hand, the study revealed that two shots of AstraZeneca were effective by 67% against the Delta variant, compared to 74.5% against the Alpha variant.
Follow the latest news on Google News
